;PMID: 10463570
;source_file_658.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:44..244] = [t:44..244]
;2)section:[e:248..302] = [t:248..302]
;3)section:[e:306..419] = [t:306..419]
;4)sentence:[e:423..510] = [t:423..510]
;5)sentence:[e:511..639] = [t:511..639]
;6)sentence:[e:640..845] = [t:640..845]
;7)sentence:[e:846..1052] = [t:846..1052]
;8)sentence:[e:1054..1287] = [t:1054..1287]
;9)sentence:[e:1288..1569] = [t:1288..1569]
;10)section:[e:1573..1618] = [t:1573..1618]

;section 0 Span:0..38
;Cancer Res. 1999 Aug 15;59(16):3861-5.
(SEC
  (FRAG (NNP:[0..6] Cancer) (NNP:[7..10] Res) (.:[10..11] .) (CD:[12..16] 1999)
        (NNP:[17..20] Aug) (CD:[21..23] 15) (CD:[23..25] ;5) (CD:[25..26] 9)
        (-LRB-:[26..27] -LRB-) (CD:[27..29] 16) (-RRB-:[29..30] -RRB-)
        (::[30..31] :) (CD:[31..34] 386) (CD:[34..37] 1-5) (.:[37..38] .)))

;sentence 1 Span:44..244
;Multimodal cancer treatment mediated by a replicating oncolytic virus that 
;delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes 
;simplex virus thymidine kinase gene therapies.
;[133..149]:substance:"oxazaphosphorine"
;[154..173]:cyp450:"cytochrome P450 2B1"
;[178..189]:substance:"ganciclovir"
;[212..228]:substance:"thymidine kinase"
(SENT
  (NP-HLN
    (NP (JJ:[44..54] Multimodal) (NN:[55..61] cancer) (NN:[62..71] treatment))
    (VP (VBN:[72..80] mediated)
      (NP (-NONE-:[80..80] *))
      (PP (IN:[81..83] by)
        (NP-LGS
          (NP (DT:[84..85] a) (VBG:[86..97] replicating)
              (JJ:[98..107] oncolytic) (NN:[108..113] virus))
          (SBAR
            (WHNP-2 (WDT:[114..118] that))
            (S
              (NP-SBJ-2 (-NONE-:[118..118] *T*))
              (VP (VBZ:[120..128] delivers)
                (NP (DT:[129..132] the)
                  (NML
                    (NML
                      (NML (NN:[133..149] oxazaphosphorine) (SYM:[149..150] /)
                           (NN:[150..153] rat))
                      
                      (NML (NN:[154..164] cytochrome) (NN:[165..169] P450))
                      (NN:[170..173] 2B1)
                      (NML-1 (-NONE-:[173..173] *P*)))
                    (CC:[174..177] and)
                    (NML
                      (NML
                        (NML (NN:[178..189] ganciclovir))
                        (SYM:[189..190] /)
                        (NML (NN:[190..196] herpes) (NN:[198..205] simplex)
                             (NN:[206..211] virus)))
                      (NML (NN:[212..221] thymidine) (NN:[222..228] kinase))
                      (NML-1 (NN:[229..233] gene) (NNS:[234..243] therapies)))))))))))
    (.:[243..244] .)))

;section 2 Span:248..302
;Aghi M, Chou TC, Suling K, Breakefield XO, Chiocca EA.
(SEC
  (FRAG (NNP:[248..252] Aghi) (NNP:[253..255] M,) (NNP:[256..260] Chou)
        (NNP:[261..263] TC) (,:[263..264] ,) (NNP:[265..271] Suling)
        (NNP:[272..274] K,) (NNP:[275..286] Breakefield) (NNP:[287..289] XO)
        (,:[289..290] ,) (NNP:[291..298] Chiocca) (NNP:[299..302] EA.)))

;section 3 Span:306..419
;Molecular Neuro-Oncology Laboratories, Neurosurgical Service, Massachusetts 
;General Hospital, Boston 02114, USA.
(SEC
  (FRAG (NNP:[306..315] Molecular) (NNP:[316..320] Neur)
        (NNP:[320..330] o-Oncology) (NNP:[331..343] Laboratories)
        (,:[343..344] ,) (NNP:[345..358] Neurosurgical) (NNP:[359..366] Service)
        (,:[366..367] ,) (NNP:[368..381] Massachusetts) (NNP:[383..390] General)
        (NNP:[391..399] Hospital) (,:[399..400] ,) (NNP:[401..407] Boston)
        (VBD:[408..413] 02114) (NNP:[413..414] ,) (NNP:[415..418] USA)
        (.:[418..419] .)))

;sentence 4 Span:423..510
;Multimodal therapy is generally more effective than single-agent treatment
;for  cancer.
(SENT
  (S
    (NP-SBJ (JJ:[423..433] Multimodal) (NN:[434..441] therapy))
    (VP (VBZ:[442..444] is)
      (ADVP (RB:[445..454] generally))
      (ADJP-PRD
        (ADJP (RBR:[455..459] more) (JJ:[460..469] effective))
        (PP (IN:[470..474] than)
          (NP (JJ:[475..487] single-agent) (NN:[488..497] treatment))))
      (PP (IN:[498..501] for)
        (NP (NN:[503..509] cancer))))
    (.:[509..510] .)))

;sentence 5 Span:511..639
;rRp450 is an engineered herpes simplex viral mutant that replicates in  and
;kills tumor cells in a relatively selective fashion.
(SENT
  (S
    (NP-SBJ (NN:[511..517] rRp450))
    (VP (VBZ:[518..520] is)
      (NP-PRD
        (NP (DT:[521..523] an) (VBN:[524..534] engineered)
          (NML (NN:[535..541] herpes) (NN:[542..549] simplex))
          (JJ:[550..555] viral) (NN:[556..562] mutant))
        (SBAR
          (WHNP-2 (WDT:[563..567] that))
          (S
            (NP-SBJ-2 (-NONE-:[567..567] *T*))
            (VP
              (VP (VBZ:[568..578] replicates)
                (PP (IN:[579..581] in)
                  (NP-1 (-NONE-:[581..581] *RNR*))))
              (CC:[583..586] and)
              (VP (VBZ:[587..592] kills)
                (NP-1 (-NONE-:[592..592] *RNR*)))
              (NP-1 (NN:[593..598] tumor) (NNS:[599..604] cells))
              (PP (IN:[605..607] in)
                (NP (DT:[608..609] a)
                  (ADJP (RB:[610..620] relatively) (JJ:[621..630] selective))
                  (NN:[631..638] fashion))))))))
    (.:[638..639] .)))

;sentence 6 Span:640..845
;It also expresses, in  infected cells, the cyclophosphamide (CPA)-sensitive
;rat cytochrome P450 2B1  (CYP2B1) and the ganciclovir (GCV)-sensitive herpes
;simplex virus thymidine  kinase (HSV-TK) transgenes.
;[683..699]:substance:"cyclophosphamide"
;[701..704]:substance:"CPA"
;[720..739]:cyp450:"cytochrome P450 2B1"
;[742..748]:cyp450:"CYP2B1"
;[758..769]:substance:"ganciclovir"
;[771..774]:substance:"GCV"
;[786..824]:substance:"herpes simplex virus thymidine  kinase"
;[826..832]:substance:"HSV-TK"
(SENT
  (S
    (NP-SBJ (PRP:[640..642] It))
    (ADVP (RB:[643..647] also))
    (VP (VBZ:[648..657] expresses) (,:[657..658] ,)
      (PP-LOC (IN:[659..661] in)
        (NP (JJ:[663..671] infected) (NNS:[672..677] cells)))
      (,:[677..678] ,)
      (NP
        (NP (DT:[679..682] the)
          (ADJP
            (NML
              (NML (NN:[683..699] cyclophosphamide))
              (NML (-LRB-:[700..701] -LRB-) (NN:[701..704] CPA)
                   (-RRB-:[704..705] -RRB-)))
            (HYPH:[705..706] -) (JJ:[706..715] sensitive))
          (NN:[716..719] rat)
          (NML
            (NML (NN:[720..730] cytochrome) (NN:[731..735] P450)
                 (NN:[736..739] 2B1))
            (NML (-LRB-:[741..742] -LRB-) (NN:[742..748] CYP2B1)
                 (-RRB-:[748..749] -RRB-)))
          (NML-1 (-NONE-:[749..749] *P*)))
        (CC:[750..753] and)
        (NP (DT:[754..757] the)
          (ADJP
            (NML
              (NML (NN:[758..769] ganciclovir))
              (NML (-LRB-:[770..771] -LRB-) (NN:[771..774] GCV)
                   (-RRB-:[774..775] -RRB-)))
            (HYPH:[775..776] -) (JJ:[776..785] sensitive))
          (NML
            (NML
              (NML (NN:[786..792] herpes) (NN:[793..800] simplex)
                   (NN:[801..806] virus))
              (NN:[807..816] thymidine) (NN:[818..824] kinase))
            (NML (-LRB-:[825..826] -LRB-) (NN:[826..832] HSV-TK)
                 (-RRB-:[832..833] -RRB-)))
          (NML-1 (NNS:[834..844] transgenes)))))
    (.:[844..845] .)))

;sentence 7 Span:846..1052
;We show that cultured rat 9L and human U87deltaEGFR  glioma cells, infected
;and lysed by rRp450, also exhibit supra-additive  sensitivity to both CPA and
;GCV, as determined by Chou-Talalay synergy analysis.
;[992..995]:substance:"CPA"
;[1000..1003]:substance:"GCV"
(SENT
  (S
    (NP-SBJ (PRP:[846..848] We))
    (VP (VBP:[849..853] show)
      (SBAR (IN:[854..858] that)
        (S
          (NP-SBJ
            (NP
              (NP (JJ:[859..867] cultured) (NN:[868..871] rat)
                  (NN:[872..874] 9L)
                (NML-2 (-NONE-:[874..874] *P*)))
              (CC:[875..878] and)
              (NP (JJ:[879..884] human) (NN:[885..897] U87deltaEGFR)
                  (NN:[899..905] glioma)
                (NML-2 (NNS:[906..911] cells))))
            (,:[911..912] ,)
            (VP (VBN:[913..921] infected) (CC:[922..925] and)
                (VBN:[926..931] lysed)
              (NP (-NONE-:[931..931] *))
              (PP (IN:[932..934] by)
                (NP-LGS (NN:[935..941] rRp450)))))
          (,:[941..942] ,)
          (ADVP (RB:[943..947] also))
          (VP (VBP:[948..955] exhibit)
            (NP
              (NP
                (ADJP (AFX:[956..961] supra) (HYPH:[961..962] -)
                      (JJ:[962..970] additive))
                (NN:[972..983] sensitivity))
              (PP (TO:[984..986] to)
                (NP (DT:[987..991] both) (NN:[992..995] CPA) (CC:[996..999] and)
                    (NN:[1000..1003] GCV))))
            (,:[1003..1004] ,)
            (SBAR-ADV (IN:[1005..1007] as)
              (S
                (NP-SBJ-1 (-NONE-:[1007..1007] *))
                (VP (VBN:[1008..1018] determined)
                  (NP-1 (-NONE-:[1018..1018] *))
                  (PP-MNR (IN:[1019..1021] by)
                    (NP
                      (NML (NNP:[1022..1026] Chou) (HYPH:[1026..1027] -)
                           (NNP:[1027..1034] Talalay))
                      (NN:[1035..1042] synergy) (NN:[1043..1051] analysis))))))))))
    (.:[1051..1052] .)))

;sentence 8 Span:1054..1287
;DNA cross-linking, assayed by ethidium bromide fluorescence, was
;significantly  inhibited in the presence of GCV, suggesting that interactions
;between the  CPA/CYP2B1 and GCV/HSV-TK gene therapies occurred at the level
;of DNA repair.
;[1054..1057]:substance:"DNA"
;[1084..1100]:substance:"ethidium bromide"
;[1163..1166]:substance:"GCV"
;[1210..1213]:substance:"CPA"
;[1214..1220]:cyp450:"CYP2B1"
;[1225..1228]:substance:"GCV"
;[1229..1235]:substance:"HSV-TK"
;[1276..1279]:substance:"DNA"
(SENT
  (S
    (NP-SBJ-2
      (NP (NN:[1054..1057] DNA) (NN:[1058..1071] cross-linking))
      (,:[1071..1072] ,)
      (VP (VBN:[1073..1080] assayed)
        (NP (-NONE-:[1080..1080] *))
        (PP-MNR (IN:[1081..1083] by)
          (NP
             (NN:[1084..1092] ethidium) (NN:[1093..1100] bromide)
            (NN:[1101..1113] fluorescence)))))
    (,:[1113..1114] ,)
    (VP (VBD:[1115..1118] was)
      (ADVP (RB:[1119..1132] significantly))
      (VP (VBN:[1134..1143] inhibited)
        (NP-2 (-NONE-:[1143..1143] *))
        (PP (IN:[1144..1146] in)
          (NP
            (NP (DT:[1147..1150] the) (NN:[1151..1159] presence))
            (PP (IN:[1160..1162] of)
              (NP (NN:[1163..1166] GCV)))))
        (,:[1166..1167] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[1167..1167] *))
          (VP (VBG:[1168..1178] suggesting)
            (SBAR (IN:[1179..1183] that)
              (S
                (NP-SBJ
                  (NP (NNS:[1184..1196] interactions))
                  (PP (IN:[1197..1204] between)
                    (NP (DT:[1205..1208] the)
                      (NML
                        (NML
                          (NML (NN:[1210..1213] CPA) (SYM:[1213..1214] /)
                               (NN:[1214..1220] CYP2B1))
                          (NML-1 (-NONE-:[1220..1220] *P*)))
                        (CC:[1221..1224] and)
                        (NML
                          (NML (NN:[1225..1228] GCV) (SYM:[1228..1229] /)
                               (NN:[1229..1235] HSV-TK))
                          (NML-1 (NN:[1236..1240] gene)
                                 (NNS:[1241..1250] therapies)))))))
                (VP (VBD:[1251..1259] occurred)
                  (PP (IN:[1260..1262] at)
                    (NP
                      (NP (DT:[1263..1266] the) (NN:[1267..1272] level))
                      (PP (IN:[1273..1275] of)
                        (NP (NN:[1276..1279] DNA) (NN:[1280..1286] repair))))))))))))
    (.:[1286..1287] .)))

;sentence 9 Span:1288..1569
;In  vivo, regression of 9L s.c. tumor volumes in athymic mice was achieved
;only by  the multimodal treatment allowed by rRp450 viral oncolysis combined
;with  CPA/CYP2B1 and GCV/HSV-TK gene therapies, whereas all other treatment 
;combinations produced only tumor growth retardation.
;[1446..1449]:substance:"CPA"
;[1450..1456]:cyp450:"CYP2B1"
;[1461..1464]:substance:"GCV"
;[1465..1471]:substance:"HSV-TK"
(SENT
  (S
    (ADVP (FW:[1288..1290] In) (FW:[1292..1296] vivo))
    (,:[1296..1297] ,)
    (NP-SBJ-2
      (NP (NN:[1298..1308] regression))
      (PP (IN:[1309..1311] of)
        (NP (NN:[1312..1314] 9L) (JJ:[1315..1319] s.c.) (NN:[1320..1325] tumor)
            (NNS:[1326..1333] volumes)))
      (PP-LOC (IN:[1334..1336] in)
        (NP (JJ:[1337..1344] athymic) (NNS:[1345..1349] mice))))
    (VP (VBD:[1350..1353] was)
      (VP (VBN:[1354..1362] achieved)
        (NP-2 (-NONE-:[1362..1362] *))
        (PP
          (ADVP (RB:[1363..1367] only))
          (IN:[1368..1370] by)
          (NP
            (NP (DT:[1372..1375] the) (JJ:[1376..1386] multimodal)
                (NN:[1387..1396] treatment))
            (VP (VBN:[1397..1404] allowed)
              (NP (-NONE-:[1404..1404] *))
              (PP (IN:[1405..1407] by)
                (NP-LGS
                  (NP (NN:[1408..1414] rRp450) (JJ:[1415..1420] viral)
                      (NN:[1421..1430] oncolysis))
                  (PP (VBN:[1431..1439] combined)
                    (PP (IN:[1440..1444] with)
                      (NP
                        (NP
                          (NML (NN:[1446..1449] CPA) (SYM:[1449..1450] /)
                               (NN:[1450..1456] CYP2B1))
                          (NML-1 (-NONE-:[1456..1456] *P*)))
                        (CC:[1457..1460] and)
                        (NP
                          (NML (NN:[1461..1464] GCV) (SYM:[1464..1465] /)
                               (NN:[1465..1471] HSV-TK))
                          (NML-1 (NN:[1472..1476] gene)
                                 (NNS:[1477..1486] therapies)))))))))))
        (,:[1486..1487] ,)
        (SBAR-ADV (IN:[1488..1495] whereas)
          (S
            (NP-SBJ (DT:[1496..1499] all) (JJ:[1500..1505] other)
                    (NN:[1506..1515] treatment) (NNS:[1517..1529] combinations))
            (VP (VBD:[1530..1538] produced)
              (NP
                (ADVP (RB:[1539..1543] only))
                (NN:[1544..1549] tumor) (NN:[1550..1556] growth)
                 (NN:[1557..1568] retardation)))))))
    (.:[1568..1569] .)))

;section 10 Span:1573..1618
;PMID: 10463570 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1573..1577] PMID) (::[1577..1578] :) (CD:[1579..1587] 10463570)
        (NN:[1588..1589] -LSB-) (NNP:[1589..1595] PubMed) (::[1596..1597] -)
        (NN:[1598..1605] indexed) (IN:[1606..1609] for)
        (NNP:[1610..1618] MEDLINE-RSB-)))
